From: kristoff@GENBANK.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 14, pt. 1, 10 April 1992
Date: 10 Apr 92 23:31:03 GMT
Distribution: bionet


NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution.  The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs.
----------------------------------------------------------------------

$$XID NIHGUIDE 19920410 V21N14 P1O2 ************************************
X-comment: RFAs described: OD-92-03

NIH GUIDE - Vol. 21, No. 14 - April 10, 1992

$$INDEX BEGIN *******************************************************

                         NOTICES

$$INDEX N1 **********************************************************

NCI OUTSTANDING INVESTIGATOR AWARD
National Cancer Institute
INDEX:  CANCER

$$INDEX N2 **********************************************************

NIH AIDS RESEARCH LOAN REPAYMENT PROGRAM
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH

$$INDEX N3 **********************************************************

HEALTH AND SAFETY GUIDELINES FOR GRANTEES AND CONTRACTORS
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION


         NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$INDEX R1 **********************************************************

A PROSPECTIVE COHORT STUDY OF CANCER AMONG MEN AND WOMEN IN
AGRICULTURE (FIELD STATIONS) (RFP NCI-CP-21096-21)
National Cancer Institute
INDEX:  CANCER

$$INDEX R2 **********************************************************

CONTINUATION OF FOLLOW-UP OF DES-EXPOSED COHORTS (RFP NCI-CP-33011-
21)
National Cancer Institute
INDEX:  CANCER

$$INDEX R3 06/10/92 *************************************************

SCIENCE TEACHING ENHANCEMENT AWARD PROGRAM (RFA OD-92-03)
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH


              ONGOING PROGRAM ANNOUNCEMENTS

$$INDEX P1 **********************************************************

INTERNATIONAL GENOME RESEARCH COLLABORATIVE PROGRAM FOR CENTRAL AND
EASTERN EUROPE (PA-92-67)
National Center for Human Genome Research
Fogarty International Center
INDEX:  HUMAN GENOME RESEARCH; FOGARTY INTERNATIONAL CENTER

$$INDEX P2 **********************************************************

INTERNATIONAL GENOME RESEARCH FELLOWSHIP PROGRAM FOR CENTRAL AND
EASTERN EUROPE (PA-92-68)
National Center for Human Genome Research
Fogarty International Center
INDEX:  HUMAN GENOME RESEARCH; FOGARTY INTERNATIONAL CENTER


                         ERRATUM

$$INDEX E1 **********************************************************

CAUSES AND EFFECTS OF ELDERLY POPULATION CONCENTRATIONS (PA-92-62)
National Institute on Aging
Agency for Health Care Policy and Research
INDEX:  AGING; HEALTH CARE POLICY RESEARCH

$$INDEX E2 **********************************************************

THE STUDY OF PATIENT OUTCOMES ASSOCIATED WITH PHARMACEUTICAL THERAPY
(RFA NS-92-03)
Agency for Health Care Policy and Research
INDEX:  HEALTH CARE POLICY RESEARCH


This publication is also available electronically to institutions via
BITNET or INTERNET.  Alternative access is through the NIH Grant Line
using a personal computer.  Contact Dr. John James at 301/496-7554
for details, or send an E-mail message to ZNS@NIHCU.

$$INDEX END *********************************************************


                         NOTICES

$$N1 BEGIN **********************************************************

NCI OUTSTANDING INVESTIGATOR AWARD

NIH GUIDE, Volume 21, Number 14, April 10, 1992

P.T. 34; K.W. 1014006

National Cancer Institute

In order to be able to meet NIH cost containment objectives (NIH
Guide, Vol. 20, No. 28, July 19, 1991), the National Cancer Institute
is currently  reviewing options for revision of the guidelines and
purposes of its Outstanding Investigator Grant (OIG) (R35) program.
To reduce additional commitments during this period of evaluation,
new type 1 applications will not be accepted for the previously
announced June 1, 1992, receipt deadline.  In the interim, NCI will
rely on careful consideration of highly meritorious competing R01
applications for funding as MERIT awards to provide longer term
support for individual projects of exceptional potential.

To avoid disruption of ongoing OIG awards, competing continuation
applications (type 2) for OIG grants that currently are in the fifth
(05) year or later will continue to be accepted and may be submitted
by June 1, 1992.

Future receipt dates and a notice of availability of revised OIG
guidelines will be published subsequently in the NIH Guide.

For additional information or for questions concerning this notice,
contact:

Mrs. Barbara S. Bynum
Director, Division of Extramural Activities
National Cancer Institute
Building 31, Room 10A03
Bethesda, MD  20892
Telephone:  (301) 496-5147
FAX:  (301) 402-0062

$$N1 END ************************************************************

$$N2 BEGIN **********************************************************

NIH AIDS RESEARCH LOAN REPAYMENT PROGRAM

NIH GUIDE, Volume 21, Number 14, April 10, 1992

P.T. 23; K.W. 0720005, 1014006

National Institutes of Health

Application Receipt Dates:  April 27, 1992,  August 1, 1992

PURPOSE

This notice is a republication, with minor modifications, of a
December 13, 1991 (Vol. 20, No. 46), issuance on this subject.  It is
being reissued to emphasize its availability.

On November 4, 1988, the United States Congress enacted Public Law
100-607, directing the National Institutes of Health (NIH) to
establish an educational loan repayment program to attract
investigators into Acquired Immunodeficiency Syndrome (AIDS)
research.  The NIH AIDS Research Loan Repayment Program (LRP), in
order to increase the number of investigators conducting AIDS
research at the NIH, invites interested health professionals to apply
for LRP participation.

The LRP may pay a maximum of $20,000 a year directly to a
participant's lenders for qualifying educational debt during an
initial, minimum two-year service period.  The actual loan repayment
is based, in part, on the availability of funding and the proportion
of the participant's qualifying debt relative to the NIH basic pay or
stipend received. Since such payments to lenders are considered
income for the participant and increases his/her Federal tax
liability, the LRP also makes payments, equal to 39 percent of the
total loan repayments, directly towards the participant's Internal
Revenue Service (IRS) account.  The LRP may make additional tax
reimbursements to those participants who show an increase in State
and/or local tax liability.  Benefits are paid in addition to a
participant's annual NIH basic pay or stipend.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This program
announcement, NIH AIDS Research Loan Repayment Program, is related to
the priority area of HIV infection.  Potential applicants may obtain
a copy of "Healthy People 2000" (Full Report:  Stock No. 017
001-00474-0) or "Healthy People 2000" (Summary Report: Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402 9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

An applicant becomes eligible for LRP participation when his/her
qualified AIDS research assignment is approved by the AIDS Research
Loan Repayment Advisory Committee (LRAC) and his/her contract is
executed.  Specific LRP applicant and participant eligibility
criteria also include the following:

(1) Applicants must be citizens or permanent residents of the United
States;

(2) Applicants must have a Ph.D., M.D., D.O., D.D.S., D.M.D., D.V.M.,
or equivalent degree;

(3) Applicants must have qualified educational debt in excess of 20
percent of their annual NIH basic pay or stipend on the date of
program eligibility resulting from governmental or commercial loans
obtained to support their undergraduate and/or graduate education;

(4) Individuals who are not NIH employees, such as Visiting Fellows,
Intramural Research Training Award (IRTA) recipients, National
Research Service Award (NRSA) recipients, Guest Researchers and
Special Volunteers, NIH, National Research Council (NRC)
Biotechnology Research Associates Program participants, and
Intergovernmental Personnel Act (IPA) participants, may NOT
participate in the LRP;

(5) Individuals employed by the NIH during the period of November 4,
1987, through November 3, 1988, are INELIGIBLE;

(6) Applicants may be appointed under a temporary or permanent
employment mechanism, if the employment has the potential to last a
minimum of two years;

(7) Individuals with existing service obligations to Federal, State,
or other entities will NOT be considered for the LRP unless deferrals
are granted for the length of their LRP service obligation; and

(8) Applicants will NOT be excluded from consideration under the LRP
on the basis of race, color, creed, religion, sex, handicap, age,
national origin, or political affiliation.

In addition, in order to qualify for repayment, LRP applicants' debts
are subject to the following limitations and restrictions:

The LRP will repay lenders for the principal, interest, and related
expenses (such as the required insurance premiums on the unpaid
balances of some loans) of qualified Government (Federal, State, and
local) and commercial educational loans obtained by participants for
the following:  (1) undergraduate, graduate, and health professional
school tuition expenses; (2) other reasonable educational expenses
required by the school(s) attended, including fees, books, supplies,
educational equipment and materials, and laboratory expenses; and (3)
reasonable living expenses, including the cost of room and board,
transportation and commuting costs, and other reasonable living
expenses as determined by the LRP.

The following loans are NOT repayable under the LRP:  (1) loans not
obtained from a Government entity or commercial lending institution,
such as loans from friends, relatives, or other private individuals;
(2) loans for which contemporaneous documentation is not available;
(3) loans or portions of loans obtained for educational or living
expenses that exceed the "reasonable" level as determined by the
standard school budget for the year in which the loan was made, and
are determined by the LRP to be unreasonable based on additional
documentation provided by the applicant; and (4) loans, financial
debts, or service obligations incurred under the Physicians Shortage
Area Scholarship Program, NRSA Program, Public Health and National
Health Service Corps Scholarship Training Program, National Health
Service Corps Scholarship Program, Armed Forces (Army, Navy, or Air
Force) Health Professions Scholarship Program, and Indian Health
Service Scholarship Program.

Loans in default, or loans not current in payment schedule, will not
be considered as qualifying for repayment. Repayments will only be
made for loans with current payment status.  During lapses in loan
repayments, due either to program administrative complications or a
break in service, participants are wholly responsible for making
payments or any other arrangements that maintain loans in a current
payment status.  Penalties assessed to participants as a result of
LRP administrative failures to maintain current payment status may be
considered for reimbursement.

Payments will NOT be made under the LRP for loans that participants
have paid prior to the program eligibility date.

RESEARCH OBJECTIVES

The LRP is designed to attract additional investigators into AIDS
research.  The LRP intends to fund individuals conducting AIDS
research as described in the following paragraphs that contain the
"Activities Constituting AIDS Research" criteria as adopted by the
LRAC on September 20, 1991:

"The following parameters define whether or not a proposed research
assignment meets the criteria for coverage under the NIH AIDS
Research Loan Repayment Program - that is, whether or not the
incumbent will be "primarily" engaged in AIDS research. "Primarily"
engaged in AIDS research is defined as AIDS research activities that
constitute at least 80 percent of a researcher's time.  Clinical
Associates whose intent is to primarily engage in AIDS research must
engage in qualified AIDS research for at least three months in the
first year of their program, with a total of fifteen months of
qualified AIDS research during their two year contract.

"AIDS research includes studies of the human immunodeficiency virus
(HIV), the pathophysiology of HIV infection, the development of
models of HIV infection and its sequelae, cofactors predisposing to
HIV infection and AIDS, or its sequelae, and the development of
vaccines and therapeutics.  More specifically, the following research
activities are included:  (1) studies of HIV and related
retroviruses; (2) studies of the mechanism(s) by which HIV and
related retroviruses establish infection and infect host cells; (3)
studies of the mechanism(s) by which HIV and related retroviruses
cause disease, including studies of the immune deficiency induced by
HIV and related retroviruses; (4) studies of the pathophysiology of
host response to HIV infection; (5) studies of in vivo or in vitro
models of human HIV infection and its sequelae; (6) epidemiologic
studies of HIV and related retrovirus infection; (7) clinical trials
involving prophylaxis or therapy for HIV infection or its sequelae;
(8) preclinical studies aimed at the development of therapy for or
prevention of HIV infection and the immunodeficiency caused by HIV
infection and its sequelae; (9) cofactors predisposing to acquiring
HIV infection; (10) basic studies and clinical trials involving
vaccines, or other immunological or chemotherapeutic interventions
for the prevention of HIV infection and its sequelae; and (11) basic
studies into the transmission of HIV involving high risk behaviors
and research concerning the interruption of transmission by
behavioral change and pharmacologic intervention.

"AIDS researchers include scientists who are intellectually engaged
in the process of providing scientific direction and guidance in
programs of original AIDS research, specifically epidemiologists,
statisticians, and others who are involved in the design and conduct
of research studies.  The duties of such scientists may include the
generation and design of studies and the collation and analysis of
data; and/or the preparation and publication, as author or co-author,
of studies in peer-reviewed journals.  AIDS researchers also include
physicians who are providing care for HIV-infected individuals who
are subjects of HIV-related research."

APPLICATION PROCEDURES

Individuals wishing to apply to the LRP must first obtain a firm
employment commitment from an Institute, Center, or Division (ICD)
Personnel Department.  An initiating official, which may be a
laboratory or branch chief, must recommend an individual for
application to the LRP, and the ICD Scientific Program Director and
ICD Director must concur.  LRP participation is contingent, in part,
upon employment with the NIH, and candidates may not be recommended
for loan repayment by an ICD until a firm employment commitment has
been made by the ICD Personnel Department.

Applicants must submit a signed contract, along with their completed
LRP application package, to be considered for participation in the
program.

At the conclusion of the initial contract, participants may reapply
and be considered for subsequent, one-year continuation contracts.
Continuation contracts are based upon the same review criteria as the
initial contract, in addition to a submission that describes AIDS
research accomplishments made during the initial contract.  These
continuation contracts are approved on a year-to-year basis and
contingent upon the appropriation and availability of funds.

REVIEW PROCEDURES

Completed applications to the LRP are reviewed by the LRAC. The LRAC,
which is composed of intramural and extramural scientific staff,
reviews, ranks, and approves or disapproves applicants.  LRAC
approval, in part, is based on the appropriateness of the applicant's
research assignment to AIDS research and the scientific merit of the
research. In addition, the credentials provided in the application
are reviewed and ranked to assess the applicant's potential to
conduct qualified AIDS research.

AWARD CRITERIA

The award of funds for approved applications is contingent, in part,
upon the availability of funds appropriated by the Congress of the
United States for the NIH.  Funds will not be awarded to disapproved
applicants.  In return for the repayment of educational loans,
participants must agree (1) to be "primarily" engaged in qualified
AIDS research, which is described above in the "Activities
Constituting AIDS Research" criteria, as NIH employees for a minimum
period of two years; (2) make payments to lenders on their own behalf
for periods of Leave Without Pay (LWOP); (3) pay monetary damages as
required in cases where the initial contract is breached; and (4) all
other provisions agreed upon in the contracts.  Substantial monetary
penalties will be imposed for breach of contract.

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.
Information regarding the LRP may be obtained by calling or writing
to:

Mr. Marc S. Horowitz, J.D.
Director, NIH AIDS Research Loan Repayment Program
Office of AIDS Research
National Institutes of Health
Building 31, Room 5C12
Bethesda, MD  20892
Telephone:  (301) 402-0192

AUTHORITY AND REGULATIONS

The LRP is described in the Catalog of Federal Domestic Assistance
No. 93.936.  Awards are made under authorization of section 487A of
the PHS Act (42 U.S.C. 288-1), as amended by section 634 of the
Health Omnibus Programs Extension of 1988 (Pub. L. 100-607).  This
program is not subject to the provisions of Executive Order 12372,
Intergovernmental Review of Federal Programs, and was granted
clearance from the Office of Management and Budget (0925-0361), under
the requirements of the Paperwork Reduction Act of 1980, on June 15,
1990.

$$N2 END ************************************************************

$$N3 BEGIN **********************************************************

HEALTH AND SAFETY GUIDELINES FOR GRANTEES AND CONTRACTORS

NIH GUIDE, Volume 21, Number 14, April 10, 1992

P.T. 34; K.W. 1014002, 0725010, 0725020

National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration

This notice is a republication, with modifications, of previous
issuances on this subject.  It is being reissued to emphasize its
continuing importance.

Organizations receiving grant or contract awards are responsible for
protecting their personnel from hazardous conditions, while the
Government, generally is not legally liable for accidents, illnesses,
or liability claims arising out of research performed under its
awards. The National Institutes of Health (NIH) and the Alcohol, Drug
Abuse, and Mental Health Administration (ADAMHA) are nonetheless
concerned that a variety of hazards may threaten the safety and
health of both laboratory and clinical research personnel.
Accordingly, the publications listed below are designed to help
identify potential hazards and inform awardee organizations and
investigators of certain guidelines and standards that should be
considered in addressing particular health and/or safety concerns.
It should be noted that significant concerns about potentially
hazardous conditions could result in grant or contract funding delays
until those concerns have been resolved to the satisfaction of the
awarding component.

1.  Types of potential hazards to research personnel include the
following:

a.  Biohazards (e.g., Human Immunodeficiency Virus, HIV; other
infectious agents; oncogenic viruses).

b.  Chemical hazards (e.g., carcinogens; chemotherapeutic agents;
other toxic chemicals; flammable or explosive materials).

c.  Radioactive materials.

2.  The following guidelines and standards contain information
designed to assist grantees and contractors in assessing potential
hazards and providing a safe work environment for research personnel.
Therefore, depending upon the particular safety hazard at issue, one
or more of these documents should be consulted by grantees or
contractors. (Items a through h).

a.  Biosafety in Microbiological and Biomedical Laboratories, U.S.
Department of Health and Human Services, Centers for Disease Control
and the National Institutes of Health, HHS Publication No. (CDC) 88-
8395.

b.  Recommendations for Prevention of HIV Transmission in Health-Care
Settings.  Morbidity and Mortality Report, August 21, 1987, Vol. 35,
No. 2S.

c.  Update:  Universal Precautions for Prevention of Transmission of
Human Immunodeficiency Virus, Hepatitis B Virus, and Other Bloodborne
Pathogens in Health-Care Settings.  Morbidity and Mortality Weekly
Report, June 24, 1988, Vol. 37, No. 24.

d.  NIH Guidelines for the Laboratory Use of Chemical Carcinogens,
NIH Publication No. 81-2385.

Single copies of the above documents (Items a through d) may be
obtained from:

Division of Safety (9/91)
Office of Research Services
National Institutes of Health
Building 31, Room 1C02
Bethesda, MD  20892

Additional copies to be purchased at a cost of $3.75/copy through:

Government Printing Office
Superintendent of Documents
Washington, DC  20402
Stock# 17-40-508-3

e.  Guidelines for Research Involving Recombinant DNA Molecules (49
FR 46266 or latest revision) and Administrative Practices Supplement.
These guidelines may be obtained from:  Office of Recombinant DNA
Activities, National Institutes of Health, Building 31, Room 4B11,
Bethesda, MD  20892.

f.  Procedures for the Domestic Handling and Transport of Diagnostic
Specimens and Etiologic Agents, National Committee for Clinical
Laboratory Standards, July 17, 1985, Vol. 5, No. 1.  These procedures
may be obtained from:  National Committee for Clinical Laboratory
Standards, 771 East Lancaster Avenue, Villanova, PA 19085.

g.  Standards issued pursuant to the National Occupational Safety and
Health Act of 1970 (29 CFR Part 1910).

Copies may be obtained from:

Occupational Safety and Health Administration
National Training Institute Building
1555 Times Drive
Des Plaines, Il  60018

h.  Standards issued pursuant to the Atomic Energy Act of 1954 (42
USC 2021).  Contact Regional Office of Nuclear Regulatory Commission.

The following materials also are recommended and may be purchased
from:

National Academy Press
2102 Constitution Avenue, N.W.
Washington, DC  20418

A.  Prudent Practices for Handling Hazardous Chemicals in the
Laboratory.  Price $19.95

B.  Prudent Practices for the Disposal of Chemicals from the
Laboratory.  Price $19.95

C.  Biosafety in the Laboratory:  Prudent Practices for Handling and
Disposal of Infectious Materials.  Price $29.95

3.  Identification of Hazards

a.  Preaward

Grant and cooperative agreement (hereafter will be referred to
grant(s)) applications and contract proposals posing special hazards
typically are identified in the review process, but such concerns can
formally be expressed by agency staff or consultants at any time
prior to award.  If these hazards are not addressed, the awarding
component must ascertain how the special hazards will be handled or
the grant/contract funding could be delayed until the matter has been
resolved to the satisfaction of the awarding component.

b.  Postaward

Grant Mechanism:  The grantee must inform the awarding component of
the nature and extent of the hazard, as well as the corrective
action(s) taken or planned to prevent future occurrence.  If the
hazard is not adequately controlled, it may create a danger and
adversely impact the activities being funded so that it impinges upon
progress, efficient and effective management of resources, and
research findings.  The adverse impact may cause the grantee to
materially fail to comply with the terms of the grant.  This may lead
the awarding office to take postaward action, including suspension or
termination of the grant, in order to resolve the situation.  (See 45
CFR 74.113 et seq. and the appeal rights set forth in 42 CFR Part 50,
subpart D and 45 CFR Part 16)    Postaward action also may be
necessary if the application had addressed the issue of special
hazards but the grantee does not adequately control the special
hazards as was indicated in the application.

Contract Mechanism:  Special hazards that are identified after an
award is made may lead to suspension or termination of work under the
contract pending corrective action by the contractor.  (See 48 CFR
12.5 concerning contract "stop work" orders and the Clause at 48 CFR
Part PHS 352.223-70, Safety and Health (APR 1984).

$$N3 END ************************************************************

         NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$R1 BEGIN NCI-CP-21096-21 ******************************************

A PROSPECTIVE COHORT STUDY OF CANCER AMONG MEN AND WOMEN IN
AGRICULTURE (FIELD STATIONS)

NIH GUIDE, Volume 21, Number 14, April 10, 1992

RFP AVAILABLE:  NCI-CP-21096-21

P.T. 34; K.W. 0715035, 0785055, 0755030

National Cancer Institute

PLEASE NOTE:  This announcement has been published in the Commerce
Business Daily.  Because of the late date of this announcement in the
Guide, it is published for information purposes only.

The National Cancer Institute (NCI) is seeking contractors to perform
the above named project.  The contracts will create a field
station(s) for epidemiologic studies in states that produce grain and
livestock and/or in states with a significant proportion of minority
farmers that produce other nonperishable commodities.  It is
anticipated that at least two field stations will be necessary to
create a large cohort (approximately 156,000 persons) that can be
followed prospectively for 10 years or more to obtain detailed
information on agricultural exposures, diet, cooking practices, and
other factors of etiologic interest for the study of cancer and other
diseases.  The field station(s) shall be located in a state(s) with
population-based cancer registries and pesticide applicator
registries with at least 20,000 registrants.  It is desirable, but
not mandatory, for the state to also have a birth defects registry.
The study is designed to investigate biomarkers of exposure and
disease.  The entire cohort will include farm owner/operators
(70,000), their spouses (56,000), or commercial and noncommercial
applicators (30,000).  The cohort will be assembled by enrolling
applicators as they come to obtain or renew a pesticide application
license at the Agricultural Extension Service Offices.  The spouses
of farm applicators will be invited to enroll in the cohort when
their spouse is enrolled.  It is anticipated that it will take three
to four years to assemble the entire cohort since licenses are
renewed on a three-four year cycle in many states.

The NCI expects to award three cost-reimbursement, completion type
contracts for a 60-month period.  The Request for Proposals (RFP) was
available on March 23, 1992 and proposals are due by April 27, 1992.
Awards are anticipated by September 30, 1992.  All responsible
sources meeting the criteria are encouraged to submit an offer and
will be considered by the NCI.  No collect calls will be accepted.
Copies of the RFP may be obtained by submitting a written request to:

Barbara A. Shadrick, Contract Specialist
Research Contracts Branch, OD
Cancer Etiology Contracts Section
National Cancer Institute
Executive Plaza South, Suite 620
Bethesda, MD  20892
Telephone:  (301) 496-8611

$$R1 END ************************************************************

$$R2 BEGIN NCI-CP-33011-21 ******************************************

CONTINUATION OF FOLLOW-UP OF DES-EXPOSED COHORTS

NIH GUIDE, Volume 21, Number 14, April 10, 1992

RFP AVAILABLE:  NCI-CP-33011-21

P.T. 34; K.W. 0715035, 0785055, 0775020

National Cancer Institute

The National Cancer Institute (NCI) is seeking investigators in a
collaborative effort to continue follow-up of surviving members of a
cohort exposed to DES given in pregnancy and designated unexposed
comparison subjects.  Each cohort shall consist of at least 300
people (mothers, daughters, and sons).  The combined cohort
(inclusive of all collaborative investigators) shall include at least
3,500 people exposed in utero (daughters and sons) and at least 2,600
women exposed during pregnancy (mothers).  Unexposed subjects that
can be compared to daughters or sons shall be included, but unexposed
subjects comparable to mothers shall not.  It is anticipated that
outcomes shall be ascertained by questionnaire and record review, not
by clinical examination. Clinical examinations shall be conducted
only for cohort members who have not been examined before, for
example, new entrants.  It should be noted that an offeror may
propose to provide the names, addresses, and other locating data to
NCI and not conduct follow-up of the cohort.  The contractor will
participate in all other contract activities, but the NCI will
provide for the follow-up of cohort members.  In addition, an offeror
may propose to participate in all other cohort activities but not to
conduct tracing of the cohort.  The NCI will trace the lost cohort
members.  These variations must be clearly noted in the proposals and
the subsequent budgets must be adjusted accordingly.  This project is
a research effort.  The NCI expects to make one cost-reimbursement,
completion type contract.  All responsible sources meeting the
criteria are encouraged to submit an offer that will be considered by
the NCI.  The Request for Proposals (RFP) was available on March 30,
1992.  The proposals are due by COB May 14, 1992 with the award
anticipated by September 30, 1992.  No collect calls will be
accepted.  Copies of the RFP may be obtained by submitting a written
request to:

Barbara A. Shadrick, Contract Specialist
Research Contracts Branch, OD
Cancer Etiology Contracts Section
National Cancer Institute
Executive Plaza South, Suite 620
Bethesda, MD  20892
Telephone:  (301) 496-8611

$$R2 END ************************************************************

$$R3 BEGIN OD-92-03 FULL-TEXT ***************************************

SCIENCE TEACHING ENHANCEMENT AWARD PROGRAM

NIH GUIDE, Volume 21, Number 14, April 10, 1992

RFA AVAILABLE:  OD-92-03

P.T. 25; K.W. 0720000, 0720005

National Institutes of Health

Letter of Intent Receipt Date:  May 10, 1992
Application Receipt Date:  June 10, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.
POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN
INQUIRIES, BELOW.

PURPOSE

The National Institutes of Health, through the National Center for
Research Resources (NCRR), invites grant applications for a pilot
Science Teaching Enhancement Award Program (STEAP).  The Science
Teaching Enhancement Award will prepare highly qualified
middle/junior and high school science teachers to become lead
teachers to work as liaisons with academic medical centers,
universities, and other health professional schools to improve
teaching in the biomedical sciences of grades 6-12.  This
announcement describes a two-year program to test the feasibility and
the effectiveness of the STEAP for improving the quality of
pre-college biomedical science education.

ELIGIBILITY REQUIREMENTS

Because of the pilot nature of this activity, eligibility will be
limited.  First, to ensure that institutions have a minimum amount of
NIH research activity upon which to draw for this initiative,
eligible institutions must be recipients of a 1991 Biomedical
Research Support Grant (BRSG) award or a 1992 Minority High School
Student Research Apprentice Program (MHSSRAP) award.  Second, to
ensure that the quality of science teaching at the 6-12 grade levels
and the science literacy of the general public will be enhanced
nationwide, eligibility is limited to those states that historically
have been relatively less competitive in obtaining NIH grant support.
For purposes of this RFA, eligibility is thus limited to FY 1991 BRSG
or FY 1992 MHSSRAP institutions in Alaska, Arkansas, Delaware,
Hawaii, Idaho, Kentucky, Maine, Mississippi, Montana, Nebraska,
Nevada, New Mexico, North Dakota, Oklahoma, Puerto Rico, South
Carolina, South Dakota,  West Virginia,  Wyoming.  In addition, if an
institution has both a BRSG and a MHSSRAP program, only one STEAP
application may be submitted.  Focusing on states that have a small
research base will make it more feasible to assess and evaluate the
success of the pilot program in producing experienced, knowledgeable
lead teachers who can act as liaisons between research institutions
and the teachers, science educators, and other administrators in the
local community school system.  In addition, by broadening the
geographic areas served, the impact of NIH current science education
activities will be expanded by stimulating the scientific interests
of a new cadre of pre-college students and teachers, and thus opening
the scientific pipeline to a wider range of future biomedical
scientists.

MECHANISM OF SUPPORT

This RFA will use the grant-in-aid for education projects (R25).
Applicants will be responsible for the planning, direction, and
conduct of the proposed program.  The total project period for
applications submitted in response to this RFA may not exceed two
years.  The anticipated award date will be September 30, 1992.

This RFA is a one-time solicitation.  At the conclusion of this pilot
activity, the NIH will assess the feasibility of continuing the
program.  Thus, no unsolicited competing continuation applications
will be accepted at the conclusion of this pilot initiative.
Although NIH hopes to continue the program beyond the pilot phase,
there is neither a guarantee of continuation, nor, if the program is
continued, is there a guarantee of its future design.

FUNDS AVAILABLE

Up to $500,000 will be available from the Office of the Director,
NIH, in Fiscal Year 1992 to support this initiative.  NIH staff
anticipate making 6-10 2-year awards using multi-year funding.  This
level of support is dependent upon the receipt of a sufficient number
of applications of high scientific merit.  Although this program is
provided for in the financial plans of the Office of the Director,
NIH, awards pursuant to this RFA are contingent upon the availability
of funds for this purpose.

RESEARCH OBJECTIVES

The objective of this RFA is to increase the number of middle/junior
and high school science teachers who are motivated to: (1) become
involved in active research projects to enhance their instructional
skills and their scientific knowledge so that current concepts in
health science can be integrated into the students' curricula, (2)
develop and test curricula for classroom settings, and (3) provide
linkages among professional scientists, teachers, and school programs
to foster mentoring and encourage the pursuit of science by students.

The two-year program should include year round activities for a core
of three lead teachers to familiarize the educators with basic
vocabulary and concepts in selected areas of biomedical science of
contemporary interest, library use and the use of computers in
teaching; provide a hands-on laboratory experience that is an
appropriate research project; development of teaching modules and
instructional materials geared to the grades taught; and other
enrichment experiences including workshops, seminars, and other
classroom activities.

LETTER OF INTENT

Prospective applicants are asked to submit, by May 10, a letter of
intent that includes a descriptive title of the proposed program, the
name, address, and telephone number of the Principal Investigator,
and the number and title of the RFA in response to which the
application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
contained is helpful in planning for the review of applications.  It
allows NIH staff to estimate the potential review workload and to
avoid possible conflict of interest in the review.

The letter of intent is to be sent to:

Dr. Marjorie A. Tingle
Director, Biomedical Research Support Program
National Center for Research Resources
Westwood Building, Room 10A11
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-6743

APPLICATION PROCEDURES

Applicants must request the RFA which contains additional information
for applying under this RFA.  Applications are to be submitted using
form PHS 398 (rev. 9/91).  These forms are available in most
institutional business and sponsored programs offices and may be
requested from the Office of Grants Inquiries, Division of Research
Grants, NIH, 5333 Westbard Avenue, Bethesda, MD 20892, telephone
(301) 496-7441.

Applications must be submitted by June 10, 1992.  Applications
submitted after this date will be returned to the applicant.

REVIEW CONSIDERATIONS

Review of the STEAP grant applications for scientific and technical
merit will be performed by an ad hoc review committee.  The top two
thirds of applications will undergo a second level review for policy
and programmatic issues by the National Advisory Research Resources
Council.

The factors to be considered with the evaluation of each application
will include: (1) the educational and scientific merit of the
proposed program; (2) the manner in which it will improve biomedical
science education at the precollege level; (3) the criteria for
selecting teachers and mentors; (4) the mixture of laboratory and
didactic exercises; (5) the quality of the proposed research
experiences; (6) the quality of the proposed enrichment experiences
and support activities; (7) the potential for substantially enhancing
precollege education by having teachers prepared to incorporate what
they have learned into their own teaching and to conduct continuing
education for their colleagues; (8) the proposal to develop improved
materials and methods for classroom use; (9) evidence of support from
school systems of potential teacher candidates; (10) willingness to
participate in the evaluation component of the program; (11) the
quality of the overall plan for administration of the program; and
(12) the potential for participant teachers to take leadership roles
in the in-service training of their peers in their home schools and
communities.

AWARD CRITERIA

In making funding decisions, the Office of the Director, NIH, and the
NCRR will give consideration to ensure program balance among various
types of programs and/or geographic distribution in the United States
and its territories.

INQUIRIES

Written and telephone requests for the RFA and the opportunity to
clarify any issues or questions from potential applicants are
welcome.

Direct requests for the RFA and inquiries regarding programmatic
issues to:

Dr. Marjorie A. Tingle
Director, Biomedical Research Support Program
National Center for Research Resources
Westwood Building, Room 10A11
Bethesda, MD  20892
Telephone:  (301) 496-6743

Direct inquiries regarding fiscal matters to:

Ms. Mary V. Niemiec
Supervisory Grants Management Specialist
Office of Grants and Contracts Management
National Center for Research Resources
Westwood Building, Room 849
Bethesda, MD  20892
Telephone:  (301) 496-9840

AUTHORITY AND REGULATIONS

Awards will be made under authorization of the Public Health Service
Act, Title III, Part A (Public Law 78-410, as amended, 42 USC 241)
and administered under PHS grants policies and Federal Regulations 42
CFR 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.

$$R3 END ************************************************************